Skip to main content
Public Health
  • Consultation
  • Closed

Public consultation on the concept paper on the detailed rules for a unique identifier for medicinal product for human use

Details

Status
Closed
Opening date
Deadline
Department
Directorate-General for Health and Food Safety

Target audience

Public health community

Why we are consulting

Directive 2011/62/EU introduces obligatory 'safety features' to allow, inter alia, verification of the authenticity of medicinal products for human use ('unique identifier'). The Directive places the Commission under an obligation to adopt delegated acts setting out the details relating to inter alia the unique identifier. This concept paper is being rolled out for public consultation with a view to preparing both the impact assessment and the delegated act.

Period of consultation

From 18 November 2011 to 27 April 2012.

Contributions to and results of the consultation

Please note that some contributors requested their responses not to be made public.

Below are the public responses to the above-mentioned public consultation:

Targeted stakeholders

All citizens and organisations are welcome to contribute to this consultation.

Objective of the consultation

Directive 2011/62/EU to fight against falsified medicines introduces obligatory "safety features" to allow, inter alia, verification of the authenticity of medicinal products for human use ("unique identifier"). The Directive places the Commission under an obligation to adopt delegated acts setting out the details relating to inter alia the unique identifier.

The consultation document

The consultation document can be downloaded here.

Protection of personal data

The policy on "protection of individuals with regard to the processing of personal data by the Community institutions" is based on Regulation (EC) N° 45/2001 of the European Parliament and of the Council of 18 December 2000. More information is available here.

Additional information:

Respond to the consultation

The response period for this consultation has ended. Thank you for your input.